A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease Article abstrac+We evaluated the frequency of depression and psychosis in 46 patients with AD and 135 control subjects with the apolipoprotein (APO) E3/3 or E3l4 genotype. Patients with AD and the APOE3/4 genotype had a more than threefold increase in the signs of depression and psychosis when compared with either patients with the APOE313 genotype or to control subjects. Our preliminary study suggests that the phenotype of AD associated with the €4 allele is more likely to include psychiatric manifestations. The €4 isoform of the apolipoprotein (apo) E gene is associated with AD.' Evaluation of the clinical phenotypes of AD with isoforms of the APOE gene may offer insight into possible roles of the apoE4 protein in AD. Lopez-Alberola et a1.2 found no differences in the psychiatric, demographic, neurologic, or neuroimaging features of 31 AD patients with the APOE4I-genotype and 31 AD patients with other APOE genotypes. However, the study was small, control subjects were not included, and the frequency of other alleles was unspecified.
We hypothesized that patients with AD and the €4 allele would be phenotypically different from patients with AD without the €4 allele and from control subjects. We focused on the presence or absence of psychiatric manifestations because the frequency of depression and psychosis is high in patients with AD3-5 and disturbances in neuronal circuitry and neurotransmitter imbalances are common to both AD and psychiatric illnesses and therefore proteins such as apoE may influence psychiatric manifestations in AD.
Methods. Data were available from a previously described, community based, longitudinal study of the elderly, representative of individuals over 65 residing in the area.6 All subjects had a neuropsychological battery, a 17- Patients were excluded from the study if they had genotypes other than APOE313 or APOE314, because these genotypes were less frequent or if they had possible AD (implying a potential additional cause for their dementia). We included patients with AD and a CDR between 0.5 (very mild ADIR and 2 (moderate AD). Subjects were divided into four categories based on the APOE3/3 or APOE314 genotype and the presence or absence of AD.
For depression, we evaluated the total HDRS score. For psychosis, we used questions dealing with delusions and hallucinations from the adapted SCID pooled for a n overall psychosis score with 1 point for each affirmative answer (maximum score of 3). Scores were evaluated both as continuous and categorical variables. For the categorical variables, we used a cutoff score of 10 or more for the HDRS (60% sensitivity and 88% specificity for the diagnosis of major depression in patients with ADI9 and psychosis was rated as present or absent.
Demographic variables were analyzed using the Student's t-test or x2 analysis and Fisher's exact tests. With control subjects of the APOE313 genotype as reference, the scores as continuous outcome variables were analyzed using analysis of variance, with and without adjusting for age, education and severity of dementia (using CDR, total recall, or Blessed score). The presence or absence of the dichotomized categorical outcome variables of HDRS and psychosis scores were analyzed using x2 analysis, Fisher's Discussion. Our results suggest that patients with AD and the APOE314 genotype may have more psychiatric impairment than their peers with the APOE313 genotype or control subjects of either genotype. The at least threefold increase in psychiatric symptomatology does not appear to be due to differences in age, education, or severity of dementia as it persisted after adjusting for them. APOE4 increases risk of AD either by altering the properties of p-amyloid or tangle formation,l and this may predispose patients with the €4 allele to increased frequency of psychiatric symptoms. Patients with AD and psychosis have an overall trend toward increased numbers of senile plaques (SPs) and tangles throughout the brain with more SPs in the presubiculum and increased neurofibrillary tangles in the middle frontal cortex as compared with AD patients without psych~sis.~ Patients with AD and depression show accelerated degeneration of the locus ceruleus and substantia nigra.4 Autopsies on patients with AD and the €4 allelelo reveal overall increased numbers of plaques and tangles when compared with patients with AD and the APOE313 genotype, with significant increases in SPs in the middle frontal, superior temporal, and inferior parietal areas and the CA1 area of the hippocampus that is near the presubiculum, although the substantia nigra and locus ceruleus were not examined.1° The 
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We did not examine disease duration. Thus, the increased frequency of psychiatric symptoms may be explained by a longer duration of AD among our APOE3f4 patients. However, this explanation is unlikely as symptoms such as depression and psychosis are poorly correlated with AD d~r a t i o n .~-~ Also, by adjusting for age and severity of dementia, we effectively adjusted for differences in ages of onset of AD among genotypes. Hence, our results cannot be explained simply by differences in ages of onset or of duration of AD between groups. Alternatively, if we postulate the psychiatric symptoms to be influenced by SP deposition, SP deposition in AD is not correlated with illness durati0n.l 
